Chronic Anticoagulation in Chronic Kidney Disease∗

Vitamin deficiencies in chronic kidney disease

Endocrine disorders in chronic kidney disease

Background and Objective: Endocrine disorders are common in patients with chronic kidney disease (CKD). The aim of the present study is reviewing available literature to give a deep understanding of complexities of endocrine disorders in chronic kidney disease. Methods: A narrative reviewing method based on the available literature was approached. Findings: Generally, when renal function de...

Anticoagulation in chronic kidney disease patients—the practical aspects

There is an increasing awareness about the risks of arterial and venous thromboembolism (TE) in hospital patients and general public which has led to consideration of thrombosis prevention measures in earnest. Early recognition of the symptoms of TE disease has led to timely administration of antiplatelet and anticoagulant drugs, translating to better outcome in many of these patients. In this ...

Oral anticoagulation in chronic kidney disease: A huge challenge.

Editorial on Poli et al. Thromb Haemost 2012; 107: 1100-1106. The prevalence of chronic kidney disease (CKD) has doubled in the past 10 years related to the rise in obesity, diabetes and hypertension, becoming recognised as a silent epidemic (1). CKD is associated with an increased risk for cardiovascular morbidity and mortality, with the frequency of atrial fibrillation (AF) being especially h...

Atrial Fibrillation and Oral Anticoagulation in Chronic Kidney Disease.

Due to several unfavorable epidemiological changes, chronic kidney disease (CKD) and treatment of its associated cardiovascular morbidity have become a worldwide problem. Thus, atrial fibrillation (AF) is the most common arrhythmia and frequently associated with renal impairment: prevalence for AF is up to 27% in long-term hemodialysis patients and in general more than 25% in all CKD patients 7...